All In Biotech

Drug Trial Radar · NCT05935176

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Phase IV Clinical Trial of Immunogenicity of ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 6 to 23 Months

Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

660

Actual

Start

Sep 20, 2023

Primary completion

May 15, 2026

Study completion Jul 15, 2026

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Jul 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 23 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the immunogenicity and immunopersistence of the ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector).The protocol consists of two parts: Part 1 enrolled 660 eligible participants aged 6 to 23 months, which has now been completed. Part 2 : Open Clinical Researchplans to enroll approximately 100 eligible participants from Part 1 who have completed immunopreservance blood sampling. Participants will receive a single booster dose of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) at age 3 years (but not yet 4 years).

Conditions

  • Epidemic Meningitis

Interventions

  • MCV4Biological

    2 dose of MCV4 on Day 0 and Month 1

  • MCV4Biological

    2 dose of MCV4 on Day 0 and Month 3

  • MCV4Biological

    1 booster dose of MCV4 at 3 years old

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Antibody positivity for A, C, Y and W135 in all subjects 6 months after 2 dose exemptionTime frame: 6 months after 2 dose exemption
  2. Seroconversion rates for serotypes A, C, Y, and W135Time frame: 30 days post-booster vaccination
  3. Geometric mean titers (GMTs) for serotypes A, C, Y, and W135Time frame: 30 days post-booster vaccination
  4. Increased incidence of adverse reactionsTime frame: Within 7 days after post-booster vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wuzhi County Center for Disease Control and Prevention

    Jiaozuo, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.